New Orders

Oxford Pharmascience Group plc

("Oxford Pharmascience" or "the Company")

Three new orders from Ache Laboratorios Farmaceuticos

Oxford Pharmascience, the specialty pharmaceutical company that uses advanced pharmaceutic technologies to reposition medicines, is pleased to announce a number of new orders from Ache Laboratorios Farmaceuticos S.A., ("Ache"), the Brazilian Pharmaceutical company with which the Company entered into an exclusive licensing and distribution agreement earlier in the year.

Having completed the first shipment in August 2011, the Company has received three subsequent orders from Ache each valued at €119,000, one of which is currently shipping with the other two to be shipped in February.Ache is one of Brazil's largest pharmaceutical companies distributing over 250 brands of prescription and generic drugs and OTC products.Under the terms of the seven year agreement, Oxford Pharmascience will supply Ache with healthcare products which will be sold under a new women's health brand, called 'Inellare'. The first is a Calcium and Vitamin D product based on Oxford Pharmascience's solid state suspension technology which allows for superior taste masking and very rapid dissolution of active ingredients. Laboratory dissolution tests have demonstrated significant improvements in dissolution of this system relative to standard calcium tablets and chewable tablets.Oxford Pharmascience expects to use its own intellectual property to develop a number of additional products for Ache, as the Brazilian pharmaceutical company expands its 'Inellare' product range. The Company has begun testing concepts in Brazil to expand the range following the launch of the initial first product.

Nigel Theobald, Chief Executive, Oxford Pharmascience Group Plc, commented: "These new orders demonstrate the success Ache is seeking to achieve with the product and the significant level of demand in this rapidly growing market. Ache is a key operator in Brazil with a high quality range of offerings, and this latest development is an excellent endorsement of our own product range."

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

Hybridan LLP (Broker)

Claire Noyce / Tim Goodman / Deepak Reddy +44 20 7947 4350

ZAI Corporate Finance (Nominated Adviser)

John Depasquale/ John Treacy +44 20 7060 2220

About Oxford Pharmascience Group Plc

Oxford Pharmascience Group Plc develops advanced yet practical pharmaceutical technologies to enable reformulation that adds value to off patent and soon to be off patent drugs. The company does not manufacture or sell its own pharmaceutical products but instead seeks to license its technologies to a network of partners, mainly leading pharmaceutical companies with Rx (prescription) and OTC (Over the Counter) branded portfolios. These partners use our technologies to reposition their products helping them sustain market share and profitability by delivering improved health outcomes and/or clinical profiles via reformulated versions of the same API (active pharmaceutical ingredient).

Oxford Pharmascience Group Plc develops platform technologies that have application across multiple drug categories and can be leveraged across a broad range of reformulation problems. This business model allows us to provide solutions across the industry and fund the ongoing development of cutting edge technologies to better serve the needs of our partners. The partner companies who adopt our technology pay an up-front license fee followed by development milestone payments and then royalties on finished products sold using the technology. OXP invests the upfront licence fee to optimise product development and to ensure seamless technology transfer to the pharmaceutical partner.

About Ache Laboratorios Farmaceuticos S.A., ("Ache")

 Established 40 years ago, Ache is the largest fully Brazilian owned pharmaceutical company and currently distributes over 250 brands of prescription and generic drugs and OTC products.

During 2009 Ache had sales revenue of over GBP780 million (R$2,157 million).

Ache's sales force makes approximately 30,000 visits to physicians a year.